Table 2 Individual study characteristics
First Author Last Name, Year | Title of Publication | Study Design | Cohort used | Sample Size | % Male | Mean age | Ethnicity | Outcome of interest |
|---|---|---|---|---|---|---|---|---|
Agrawal, 2011 | A Genome-wide Association Study of DSM-IV Cannabis Dependence | Case–Control | SAGE | 3054 | NR | 39.00 | 2019 European-Americans, 1035 African Americans | Life-time history of DSM-IV cannabis dependence, modified to included cannabis withdrawal |
Agrawal, 2014 | DSM-5 Cannabis Use Disorder: A Phenotypic and Genomic Perspective | Case–control | SAGE | 3053 | 49% | 38.10 | 2018 European-Americans, 1035 African Americans | DSM-5 cannabis use disorder factor scores |
Demontis, 2019 | Genome-wide association study implicates CHRNA2 in cannabis use disorder | Case-cohort | iPSYCH | CUD: 2387 Control: 48,985 Total: 51,372 | NR | CUD: 24.77 Control: 22.67 | European | International Statistical Classification of Disease and Related Health Problems, 10th revision (ICD-10) diagnosis reflecting problematic and persistent use of cannabis |
Minica, 2015 | Heritability, SNP- and Gene-Based Analyses of Cannabis Use Initiation and Age at Onset | Cohort | Netherlands twin registry | 6744 | 39.1% | 39.09 | European | Self-reported use of cannabis ever in lifetime and self-reported age of onset of cannabis use |
Pasman, 2018 | GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal effect of schizophrenia liability | Cohort | ICC study | 35,297 | 44.3% | 35.7 | European | Any cannabis use within lifetime |
UK Biobank | 126,785 | 43.7% | 55 | |||||
23andMe | 22,683 | NR | NR | |||||
Sherva, 2016 | Genome-wide Association Study of Cannabis Dependence Severity, Novel Risk Variants, and Shared Genetic Risks | Cohort/Case-cohort | Yale-Penn, SAGE, ICGHD | 14,754 | 53.4% | 39.24 | 8754 European-American, 6000 African American | Criterion count for DSM-IV Cannabis Dependence |